LC-MS/MS quantification of parathyroid hormone fragment 1-34 in human plasma

Bioanalysis

Volumn 5, Issue 4, 2013, Pages 415-422

  MacNeill, Robert ^a   Stromeyer, Ryan ^a   Urbanowicz, Bryan ^a   Acharya, Vishva ^a   Moussallie, Marc ^a  

^a Huntingdon Life Sciences ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE[1-34];

ACCURACY; ANALYTICAL PARAMETERS; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; ENZYME ACTIVITY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; STATISTICAL ANALYSIS; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; HUMANS; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TERIPARATIDE;

EID: 84874095969     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.334     Document Type: Article

References (14)

1. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin. Ther. 26(6) 841-854 (2004). (Pubitemid 38943033)
2. Kimmel D, Bozzato R, Kronis K, Coble T, Sindrey D, Kwong P, Recker R. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132, 1577-1584 (1993). (Pubitemid 23110527)
3. Seibel S, Lade D, Hartke J, Wehmeyer K. Validation and application of an immunoradiometric assay for the determination of human parathyroid hormone fragment 1-34 in dog plasma following subcutaneous and intravenous administration. J. Pharm. Biomed. Anal. 14 1699-1707 (1996). (Pubitemid 26306908)
4. Hämmerle S, Mindeholm L, Launonen A et al. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone 50, 965-973 (2012).
5. Hu Z, Nui H, Zang S, Li H, Sang G, Li B. Recombinant human parathyroid hormone 1-34: pharmacokinetics, tissue distribution and excretion in rats. Int. J. Pharmaceutics 317, 144-154 (2006).
6. Tamvakopoulos C. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Mass Spectrom. Rev. 26, 389-402 (2007).
7. van den Broek I, Sparidans R, Schellens J, Beijnen J. Quantitative bioanalysis of peptides by liquid chromatography coupled to tandem mass spectrometry. J. Chrom. B 872, 1-22 (2008).
8. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 3(12) 1379-1397 (2011).
9. Li F, Fast D, Michael S. Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. Bioanalysis 3(21), 2459-2480 (2011).
10. Kay R, Roberts A. Bioanalysis of biotherapeutic proteins and peptides: immunological or MS approach? Bioanalysis 4(8), 857-860 (2012).
11. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), MD, USA (2001).
12. Smith G. Bioanalytical method validation: notable points in the 2009 draft EMA Guidelines and differences with the 2001 FDA Guidance. Bioanalysis 2(5), 929-935 (2010).
13. Smith G. European Medicines Agency guideline on bioanalytical method validation: what more is there to say? Bioanalysis 4(8) 865-868 (2012).
14. High Sensitivity Human PTH (1-34) ELISA Kit. Cat.# 60-3900, Immutopics Inc., CA, USA (2011).